Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioavailability of Simurosertib in Advanced Solid Tumors
NCT03708211Phase 1Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Mar 2019
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of simurosertib in solid tumor (advanced stage) (4 arms), sponsored by Millennium Pharmaceuticals. Primary endpoints: Maximum Observed Plasma Concentration, Area Under the Plasma Concentration-time Curve From Time 0 to Last Quantifiable Concentration and 1 more. Started Mar 2019; status: completed.
02
Drugs
simurosertib
03
Conditions
solid tumor (advanced stage)
Beyond the preview
Go deeper on NCT03708211.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03708211.